Diabetes and heart failure outcomes

Overview

Prof Mark Petrie (University of Glasgow, Glasgow, UK) joins Dr Mikhail N Kosiborod (Saint Luke's Mid America Heart Institute, Kansas City, US) to discuss heart failure in patients with diabetes with consideration to new data emerging from SGLT2 inhibitors and GLP-1 Receptor Agonists.

This discussion was supported by an unrestricted educational grant from Novo Nordisk.

Series overview

Part 1

Diabetes and Heart Failure Outcomes

Prof Mark Petrie (University of Glasgow, Glasgow, UK) joins Dr Mikhail N Kosiborod (Saint Luke's Mid America Heart Institute, Kansas City, US) to discuss heart failure in patients with diabetes.

1 session
Diabetes and Heart Failure Outcomes	Watch now

Part 2

SGLT2 Inhibitors in Heart Failure

Prof Mark Petrie (University of Glasgow, Glasgow, UK) joins Dr Mikhail N Kosiborod (Saint Luke's Mid America Heart Institute, Kansas City, US) to discuss heart failure in patients with diabetes.

1 session
SGLT2 Inhibitors in Heart Failure	Watch now

Part 3

GLP-1 Receptor Agonists in Heart Failure

Prof Mark Petrie (University of Glasgow, Glasgow, UK) joins Dr Mikhail N Kosiborod (Saint Luke's Mid America Heart Institute, Kansas City, US) to discuss the potential benefits of glucagon-like peptide 1 (GLP1) receptor agonists for patients with heart failure. They summarise trials that looked into novel antidiabetic agents to date (FIGHT, HARMONY and LIVE). Dr Kosiborod reviews the latest guidelines reflecting on the data. Prof Petrie outlines the potential mechanism behind the benefits of GLP1 receptor agonists in MACE-like events. They discusses the role of novel antidiabetic agents in the treatment of heart failure with preserved ejection fraction and heart failure with reduced ejection fraction.

1 session
GLP-1 Receptor Agonists in Heart Failure	Watch now

Faculty Biographies

Mikhail Kosiborod

Cardiologist

Dr Mikhail Kosiborod is a cardiologist who serves as Vice President of Research at Saint Luke's Health System, and Professor of Medicine at the University of Missouri-Kansas City, US.

He is also Director of Cardiometabolic Research and Co-Director of the Saint Luke’s Michael & Marlys Haverty Cardiometabolic Center of Excellence at Saint Luke's Mid America Heart Institute. Dr Kosiborod is an internationally-recognised expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes.

Dr Kosiborod is involved in the leadership of numerous clinical trials and multi-center registries, and is currently the principal investigator of several investigator-initiated, multi-center trials in diabetes and cardiovascular disease.

View full profile

Mark Petrie

Professor/Honorary Consultant (Institute of Cardiovascular & Medical Sciences)

Professor Mark Petrie worked as an interventional cardiologist before his professorship at University of Glasgow. His interests include revascularization in heart failure, diabetes and cardiovascular disease and cardio-oncology.